Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3785-3799

  Jurmeister, Sarah ^a   Ramos Montoya, Antonio ^a   Neal, David E ^a   Fryer, Lee G D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

AMPK; Androgen receptor; Cancer metabolism; Prostate cancer; Transcription

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; ANDROGEN RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; JANUS KINASE; KALLIKREIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; AR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER INHIBITION; CELL METABOLISM; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; NEGATIVE FEEDBACK; NUCLEAR LOCALIZATION SIGNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UPREGULATION; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; TUMOR CELL CULTURE;

AMP-ACTIVATED PROTEIN KINASES; CELL NUCLEUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84903532323     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1997     Document Type: Article

References (82)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Denmeade SR and Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002; 2(5):389-396.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-39.
4. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T and Kallioniemi OP. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57(2):314-319.
5. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML and Balk SP. Androgen receptor remains critical for cell-cycle progression in androgenindependent CWR22 prostate cancer cells. Am J Pathol. 2006; 169(2):682-696.
6. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B and Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999; 59(11):2511-2515.
7. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000; 6(6):703-706.
8. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS and Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61(11):4315-4319.
9. Flavin R, Zadra G and Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2010; 223(2):283-294.
10. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
11. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011; 30(13):2719-2733.
12. Swinnen JV, Esquenet M, Goossens K, Heyns W and Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 1997; 57(6):1086-1090.
13. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S and Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003; 1(10):707-715.
14. Shurbaji MS, Kalbfleisch JH and Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol. 1996; 27(9):917-921.
15. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, Acquafondata M and Pflug BR. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol. 2006; 37(4):401-409.
16. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D and Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287(13):1662-1670.
17. Mukherji M, Schofield CJ, Wierzbicki AS, Jansen GA, Wanders RJ and Lloyd MD. The chemical biology of branched-chain lipid metabolism. Prog Lipid Res. 2003; 42(5):359-376.
18. Davies SP, Hawley SA, Woods A, Carling D, Haystead TA and Hardie DG. Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. Eur J Biochem. 1994; 223(2):351-357.
19. Woods A, Cheung PC, Smith FC, Davison MD, Scott J, Beri RK and Carling D. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem. 1996; 271(17):10282-10290.
20. Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q, Brown M, Means AR and McDonnell DP. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgendependent migration of prostate cancer cells. Cancer Res. 2011; 71(2):528-537.
21. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV and Frigo DE. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alphamediated metabolic switch. Oncogene. 2013.
22. Pearson HB, McCarthy A, Collins CM, Ashworth A and Clarke AR. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 2008; 68(7):2223-2232.
23. Wright JL and Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a populationbased case-control study. Cancer Causes Control. 2009; 20(9):1617-1622.
24. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35(2):299-304.
25. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-1305.
26. Xiang X, Saha AK, Wen R, Ruderman NB and Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-167.
27. Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y, Wu X, Alekseyev YO, Lenburg ME, Hu GF and Luo Z. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene. 2009; 28(18):1993-2002.
28. Sauer H, Engel S, Milosevic N, Sharifpanah F and Wartenberg M. Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase. Int J Oncol. 2012; 40(2):501-508.
29. Zhou J, Yang Z, Tsuji T, Gong J, Xie J, Chen C, Li W, Amar S and Luo Z. LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene. 2011; 30(16):1892-1900.
30. Apontes P, Leontieva OV, Demidenko ZN, Li F and Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2(3):222-233.
31. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J and Tsakiridis T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys. 2010; 78(1):221-229.
32. Lin YC, Wu MH, Wei TT, Huang WC, Huang LY, Lin YT and Chen CC. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget. 2014; 5(1):298-308.
33. Zakikhani M, Dowling RJ, Sonenberg N and Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2008; 1(5):369-375.
34. Lin VC, Tsai YC, Lin JN, Fan LL, Pan MH, Ho CT, Wu JY and Way TD. Activation of AMPK by Pterostilbene Suppresses Lipogenesis and Cell-Cycle Progression in p53 Positive and Negative Human Prostate Cancer Cells. J Agric Food Chem. 2012; 60(25):6399-6407.
35. Lee CR, Chun JN, Kim SY, Park S, Kim SH, Park EJ, Kim IS, Cho NH, Kim IG, So I, Kim TW and Jeon JH. Cyclosporin A suppresses prostate cancer cell growth through CaMKKbeta/AMPK-mediated inhibition of mTORC1 signaling. Biochem Pharmacol. 2012.
36. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A and Collins SP. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther. 2009; 8(4):733-741.
37. Chhipa RR, Wu Y and Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal. 2011; 23(9):1466-1472.
38. Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS and Ha J. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res. 2009; 315(14):2433-2441.
39. Martinez Marignac VL, Smith S, Toban N, Bazile M and Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPKmediated energetic re-programming. Oncotarget. 2013; 4(12):2550-2566.
40. Anisimov VN. Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer. Aging (Albany NY). 2013; 5(5):337-338.
41. Blagosklonny MV. Selective anti-cancer agents as antiaging drugs. Cancer Biol Ther. 2013; 14(12):1092-1097.
42. Zhou G, Sebhat IK and Zhang BB. AMPK activators-potential therapeutics for metabolic and other diseases. Acta Physiol (Oxf). 2009; 196(1):175-190.
43. Fogarty S and Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010; 1804(3):581-591.
44. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, et al. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science. 2006; 313(5795):1929-1935.
45. Inoki K, Zhu T and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115(5):577-590.
46. Corradetti MN, Inoki K, Bardeesy N, DePinho RA and Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004; 18(13):1533-1538.
47. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30(2):214-226.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.
49. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267-273.
50. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castrationresistant prostate cancer. Nature. 2012; 487(7406):239-243.
51. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
52. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA and Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005; 8(5):393-406.
53. Wang J, Weng J, Cai Y, Penland R, Liu M and Ittmann M. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 2006; 66(8):847-857.
54. Weng J, Wang J, Hu X, Wang F, Ittmann M and Liu M. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer. 2006; 118(6):1471-1480.
55. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP and Rieber EP. D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun. 2004; 322(1):239-249.
56. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ and Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18(3):283-293.
57. Nader N, Ng SS, Lambrou GI, Pervanidou P, Wang Y, Chrousos GP and Kino T. AMPK regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 MAPK. Mol Endocrinol. 2010; 24(9):1748-1764.
58. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C and Carter KC. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997; 43(1):69-77.
59. Magee JA, Chang LW, Stormo GD and Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology. 2006; 147(1):590-598.
60. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS and Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009; 27(12):2022-2029.
61. Shen M, Zhang Z, Ratnam M and Dou QP. The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. J Cell Physiol. 2013.
62. Demir U, Koehler A, Schneider R, Schweiger S and Klocker H. Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer. 2014; 14(1):52.
63. Quarmby VE, Yarbrough WG, Lubahn DB, French FS and Wilson EM. Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol. 1990; 4(1):22-28.
64. Krongrad A, Wilson CM, Wilson JD, Allman DR and McPhaul MJ. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol. 1991; 76(1-3):79-88.
65. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC and Sultan C. Trafficking of the androgen receptor in living cells with fused green fluorescent proteinandrogen receptor. Mol Cell Endocrinol. 1997; 129(1):17-26.
66. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-3586.
67. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S and Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71(13):4366-4372.
68. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D and Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994; 353(1):33-36.
69. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275(1):223-228.
70. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N and Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med. 2014.
71. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS and LeffT. Regulation of transcription by AMPactivated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem. 2001; 276(42):38341-38344.
72. Wu L, Huang XJ, Yang CH, Deng SS, Qian M, Zang Y and Li J. 5'-AMP-activated protein kinase (AMPK) regulates progesterone receptor transcriptional activity in breast cancer cells. Biochem Biophys Res Commun. 2011; 416(1-2):172-177.
73. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML and Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000; 275(27):20853-20860.
74. Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J, Eto M, Uchiumi T, Fujimoto N and Naito S. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate. 2010; 70(5):540-554.
75. Kefas BA, Cai Y, Ling Z, Heimberg H, Hue L, Pipeleers D and Van de Casteele M. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol. 2003; 30(2):151-161.
76. Lee YM, Uhm KO, Lee ES, Kwon J, Park SH and Kim HS. AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway. Biochem Biophys Res Commun. 2008; 370(4):641-645.
77. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH and Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55(9):2562-2570.
78. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM and Weber MJ. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol. 2006; 20(3):503-515.
79. Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M and Belfiore A. Metformin Inhibits Androgen-Induced Igf-Ir Upregulation in Prostate Cancer Cells by Disrupting Membrane Initiated Androgen Signaling. Endocrinology. 2014:en20131925.
80. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80.
81. Cairns JM, Dunning MJ, Ritchie ME, Russell R and Lynch AG. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics. 2008; 24(24):2921-2922.
82. Dunning MJ, Smith ML, Ritchie ME and Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics. 2007; 23(16):2183-2184.